Browse HPD

Summary
SymbolHPD
Name4-hydroxyphenylpyruvate dioxygenase
Aliases 4-HPPD; 4HPPD; GLOD3; glyoxalase domain containing 3; HPPDASE; 4-hydroxyphenylpyruvic acid oxidase
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00903 Glyoxalase/Bleomycin resistance protein/Dioxygenase superfamily
Function

Key enzyme in the degradation of tyrosine.

> Gene Ontology
 
Biological Process GO:0006520 cellular amino acid metabolic process
GO:0006558 L-phenylalanine metabolic process
GO:0006559 L-phenylalanine catabolic process
GO:0006570 tyrosine metabolic process
GO:0006572 tyrosine catabolic process
GO:0009063 cellular amino acid catabolic process
GO:0009072 aromatic amino acid family metabolic process
GO:0009074 aromatic amino acid family catabolic process
GO:0016054 organic acid catabolic process
GO:0019439 aromatic compound catabolic process
GO:0044282 small molecule catabolic process
GO:0046395 carboxylic acid catabolic process
GO:1901361 organic cyclic compound catabolic process
GO:1901565 organonitrogen compound catabolic process
GO:1901605 alpha-amino acid metabolic process
GO:1901606 alpha-amino acid catabolic process
Molecular Function GO:0003868 4-hydroxyphenylpyruvate dioxygenase activity
GO:0016701 oxidoreductase activity, acting on single donors with incorporation of molecular oxygen
GO:0016702 oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen
GO:0051213 dioxygenase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00130 Ubiquinone and other terpenoid-quinone biosynthesis
hsa00350 Tyrosine metabolism
hsa00360 Phenylalanine metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-6788656: Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism
R-HSA-1430728: Metabolism
R-HSA-71291: Metabolism of amino acids and derivatives
R-HSA-71182: Phenylalanine and tyrosine catabolism
Summary
SymbolHPD
Name4-hydroxyphenylpyruvate dioxygenase
Aliases 4-HPPD; 4HPPD; GLOD3; glyoxalase domain containing 3; HPPDASE; 4-hydroxyphenylpyruvic acid oxidase
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HPD and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolHPD
Name4-hydroxyphenylpyruvate dioxygenase
Aliases 4-HPPD; 4HPPD; GLOD3; glyoxalase domain containing 3; HPPDASE; 4-hydroxyphenylpyruvic acid oxidase
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HPD in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolHPD
Name4-hydroxyphenylpyruvate dioxygenase
Aliases 4-HPPD; 4HPPD; GLOD3; glyoxalase domain containing 3; HPPDASE; 4-hydroxyphenylpyruvic acid oxidase
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HPD in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.8560.203
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0220.984
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.4810.115
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.8240.0879
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2180.842
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.5920.242
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5190.542
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0090.995
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.6930.58
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7570.642
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7820.732
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.90.00755
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HPD in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolHPD
Name4-hydroxyphenylpyruvate dioxygenase
Aliases 4-HPPD; 4HPPD; GLOD3; glyoxalase domain containing 3; HPPDASE; 4-hydroxyphenylpyruvic acid oxidase
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HPD. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHPD
Name4-hydroxyphenylpyruvate dioxygenase
Aliases 4-HPPD; 4HPPD; GLOD3; glyoxalase domain containing 3; HPPDASE; 4-hydroxyphenylpyruvic acid oxidase
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HPD. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HPD.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHPD
Name4-hydroxyphenylpyruvate dioxygenase
Aliases 4-HPPD; 4HPPD; GLOD3; glyoxalase domain containing 3; HPPDASE; 4-hydroxyphenylpyruvic acid oxidase
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HPD. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHPD
Name4-hydroxyphenylpyruvate dioxygenase
Aliases 4-HPPD; 4HPPD; GLOD3; glyoxalase domain containing 3; HPPDASE; 4-hydroxyphenylpyruvic acid oxidase
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HPD expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHPD
Name4-hydroxyphenylpyruvate dioxygenase
Aliases 4-HPPD; 4HPPD; GLOD3; glyoxalase domain containing 3; HPPDASE; 4-hydroxyphenylpyruvic acid oxidase
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HPD and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHPD
Name4-hydroxyphenylpyruvate dioxygenase
Aliases 4-HPPD; 4HPPD; GLOD3; glyoxalase domain containing 3; HPPDASE; 4-hydroxyphenylpyruvic acid oxidase
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HPD collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting HPD.
ID Name Drug Type Targets #Targets
DB00348NitisinoneSmall MoleculeHPD1
DB02850(1-Tert-Butyl-5-Hydroxy-1h-Pyrazol-4-Yl)-(6-Methanesulfonyl-4'-Methoxy-2-Methyl-Biphenyl-3-Yl)-MethanoneSmall MoleculeHPD1